MedeliX
Start asking

pazopanib

Votrient · ATC code L01XE11

Brand names: Votrient, Pazopanib Devatis, Pazopanib Al, Pazopanib Beta, Pazopanib Bluepharma, Pazopanib Glenmark, Pazopanib Stada, Pazopanib Viatris, Pazopanib Zentiva

Key facts
Active substance
pazopanib
Drug class
ALK inhibitor
ATC code
L01XE11
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Votrient 200 mg film-coated tablets / Votrient 400 mg film-coated tablets
Marketing authorisation holder
Novartis Europharm Limited
Information as of
2026-10-28

Key facts

Pazopanib (Votrient, film-coated tablets) is an oral tyrosine kinase inhibitor. It is used for advanced renal cell carcinoma and selected soft-tissue sarcomas.

What it is used for

  • Adults with advanced renal cell carcinoma as first-line treatment or after prior cytokine therapy.
  • Adults with selective subtypes of advanced soft-tissue sarcoma after chemotherapy for metastatic disease or progression within 12 months after (neo)adjuvant therapy.

Dosing

  • Recommended dose: 800 mg once daily; dose changes in 200 mg steps, not exceeding 800 mg.
  • Take without food, at least one hour before or two hours after a meal; do not break or crush tablets.
  • Liver: mild abnormalities 800 mg; moderate hepatic impairment (bilirubin >1.5 to 3 x ULN) 200 mg once daily; not recommended in severe impairment.
  • If a strong CYP3A4 inhibitor cannot be avoided: 400 mg daily.
  • Do not use in children younger than 2 years; caution with creatinine clearance below 30 ml/min.

Contraindications

  • Hypersensitivity to the active substance or any of the excipients.

Important warnings

  • Hepatic failure including fatalities; check liver tests before and during treatment.
  • Hypertension including hypertensive crisis; control blood pressure before starting and check within one week of starting.
  • QT prolongation and torsade de pointes, arterial thrombotic events and haemorrhage, some fatal.
  • Stop treatment at least 7 days before scheduled surgery (wound healing).
  • Hypothyroidism; measure thyroid function at baseline.

Side effects

  • Very common (≥10%): diarrhoea, hair colour change, skin hypopigmentation, exfoliative rash, hypertension, nausea, headache, fatigue, anorexia, vomiting, dysgeusia, stomatitis, weight decreased, elevated transaminases.
  • Serious (<1%): stroke, myocardial ischaemia and infarction, GI perforation and fistula, QT prolongation, haemorrhage; in sarcoma also venous thromboembolism and pneumothorax.

Interactions

  • Strong CYP3A4 inhibitors (e.g. ketoconazole) increase exposure; avoid or reduce the dose.
  • Medicines that raise gastric pH (e.g. esomeprazole) reduce bioavailability by about 40%; if a PPI is needed, take pazopanib in the evening without food together with the PPI.
  • With simvastatin, increased risk of ALT elevations.

Pregnancy and breastfeeding

  • Should not be used during pregnancy unless the woman's clinical condition requires it.
  • Women of childbearing potential: adequate contraception during treatment and for at least 2 weeks after the last dose.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • VotrientNovartis Europharm Limited · EMEA/H/C/001141

Source: European Medicines Agency (EMA), product information

Austria

  • Pazopanib DevatisDevatis Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • Pazopanib AlAliud Pharma Gmbh · 1 register entry
  • Pazopanib BetaBetapharm Arzneimittel Gmbh · 1 register entry
  • Pazopanib BluepharmaBluepharma Indústria Farmacêutica S.A. · 1 register entry
  • Pazopanib DevatisDevatis Gmbh · 1 register entry
  • Pazopanib GlenmarkGlenmark Arzneimittel Gmbh · 1 register entry
  • Pazopanib StadaStadapharm Gmbh · 2 register entries
  • Pazopanib ViatrisViatris Germany Gmbh · 1 register entry
  • Pazopanib ZentivaZentiva Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • VotrientNOVARTİS SAĞLIK GIDA VE TARIM ÜRÜNLERİ SAN. VE TİC. A.Ş. · 4 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 28 more European countries
Belgium
Pazopanib Accord, Pazopanib Eg
Bulgaria
Алуниб, Пазопаниб G.L. Pharma, Пазопаниб Акорд, Пазопаниб Зентива, Пазопаниб Тева, Пазопаниб Фармасайънс, Пазофронт
Croatia
Pazopanib Accord, Pazopanib Frontier, Pazopanib Pharmascience, Pazopanib Sandoz, Pazopanib Teva, Pazopanib Zentiva, Pyzypi
Cyprus
Pazopanib Sapiens, Pazorem
Czechia
Pazopanib Accord, Pazopanib Sandoz, Pazopanib Viatris, Pazopanib Zentiva, Pyzypi
Denmark
Pazopanib Accord, Pazopanib Glenmark, Pazopanib Newbury, Pazopanib Stada, Pazopanib Viatris, Pazopanib Zentiva
Estonia
Pazopanib Accord, Pazopanib Teva, Pazopanib Viatris, Pazopanib Zentiva
Finland
Pazopanib Accord, Pazopanib Glenmark, Pazopanib Stada, Pazopanib Zentiva
France
Pazopanib Accord, Pazopanib Biogaran, Pazopanib Eg, Pazopanib Stada, Pazopanib Teva, Pazopanib Viatris, Pazopanib Zentiva
Greece
Pazopanib Accord, Pazopanib Stada, Pazopanib Teva
Hungary
Pazopanib Accord, Pazopanib G.L. Pharma, Pazopanib Gedeon Richter, Pazopanib Glenmark, Pazopanib Onkogen, Pazopanib Pharmascience, Pazopanib Sandoz, Pazopanib Stada, Pazopanib Teva, Pazopanib Viatris, Pazopanib Zentiva, Pyzypi
Iceland
Pazopanib Adalvo, Pazopanib Stada, Pazopanib Viatris, Votrient
Ireland
Pazopanib Accord, Pazopanib Reddy, Pazopanib Rowex, Pazopanib Teva
Italy
Pazopanib Accord, Pazopanib Dr. Reddy’s, Pazopanib Eg, Pazopanib Glenmark, Pazopanib Mylan, Pazopanib Sandoz, Pazopanib Teva, Pazopanib Zentiva
Latvia
Pazopanib Accord, Pazopanib Teva, Pazopanib Viatris, Pazopanib Zentiva
Liechtenstein
Votrient
Lithuania
Pazopanib Accord, Pazopanib Auxilia, Pazopanib Teva, Pazopanib Viatris, Pazopanib Zentiva
Luxembourg
Pazopanib Eg, Pazopanib Pazopanib Eg
Malta
Pazopanib Pharmacare, Pazopanib Pharos, Pazopanib Torrent
Netherlands
Pazopanib Accord, Pazopanib Cf, Pazopanib Devatis, Pazopanib Glenmark, Pazopanib Reddy, Pazopanib Teva, Pazopanib Viatris
Norway
Pazopanib Accord, Pazopanib Glenmark, Pazopanib Newbury, Pazopanib Stada, Pazopanib Viatris, Pazopanib Zentiva, Votrient
Poland
Pazopanib Accord, Pazopanib Glenmark, Pazopanib Reddy, Pazopanib Sandoz, Pazopanib Stada, Pazopanib Tzf, Pazopanib Viatris, Pazopanib Zentiva
Portugal
Pazopanib Accord, Pazopanib Bluepharma, Pazopanib Mylan, Pazopanib Pls, Pazopanib Stada, Pazopanib Teva
Romania
Pazopanib Accord, Pazopanib Dr. Reddys, Pazopanib Frontier, Pazopanib Teva, Pazopanib Zentiva, Pyzypi
Slovakia
Pazopanib Accord, Pazopanib G.L. Pharma, Pazopanib Gedeon Richter, Pazopanib Glenmark, Pazopanib Sandoz, Pazopanib Stada, Pazopanib Teva, Pazopanib Zentiva
Slovenia
Pazopanib Accord, Pazopanib Teva
Spain
Pazopanib Accord, Pazopanib Dr. Reddys, Pazopanib Glenmark, Pazopanib Stada
Sweden
Pazopanib Accord, Pazopanib Glenmark, Pazopanib Newbury, Pazopanib Stada, Pazopanib Zentiva

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Votrient – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/votrient-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC L01XE.

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.